一项新西兰研究发现, 药用大麻中的CBD显著减少了子宫内膜异位症的疼痛, 改善了生活质量, 副作用很少. A New Zealand study found CBD from medicinal cannabis significantly reduced endometriosis pain and improved quality of life with few side effects.

新西兰对有内分泌硬化症的28人进行的一项研究发现,药用大麻,特别是《生物多样性公约》,在0至10的尺度上将骨盆疼痛从平均5.4降低到3.7,并在12周内改善了睡眠、焦虑和生活质量。 A New Zealand study of 28 people with endometriosis found that medicinal cannabis, particularly CBD, reduced pelvic pain from an average of 5.4 to 3.7 on a 0–10 scale and improved sleep, anxiety, and quality of life over 12 weeks. 一些与会者报告了改变生命的好处,包括重返工作岗位和计划怀孕,与类阿片相比几乎没有副作用。 Some participants reported life-changing benefits, including returning to work and planning pregnancy, with few side effects compared to opioids. 新西兰首次进行此类预期试验,得到了内分泌硬化倡导者的支持,突出表明需要进行更大规模的长期研究,以确认安全和有效性。 The first prospective trial of its kind in New Zealand, it was supported by endometriosis advocates and highlights the need for larger, long-term studies to confirm safety and effectiveness.